ARTICLE | Clinical News
CCX507: Phase I data
June 10, 2013 7:00 AM UTC
A double-blind, placebo-controlled Phase I trial in healthy volunteers showed that 3, 10 and 30 mg doses of CCX507 were well tolerated with no serious events or withdrawals due to adverse events repor...